S132: Updated Results of Ven-a-Qui Study: A Phase 1-2 Trial to Assess the Safety and Efficacy of Triplets for Newly Diagnosed Unfit Aml Patients: Azacitidine or Low-Dose Cytarabine With Venetoclax and Quizartinib

Burgués, Juan Miguel Bergua; Rodríguez‐Veiga, Rebeca; Ferri, Ivana; Calmet, Ferran Vall-Llovera; Garcia-Guiñon, Antonio; Espuch, Joaquín Gómez; Colorado, Mercedes; Casas-Avilés, Ignacio; Esteve, Jordi; Sampol, Antònia; Verdugo, Maria Victoria; Ramos, Fernando; Valero, Marta; Cruz, Evelyn Gloria Acuna; Boluda, Blanca; Miñana, Laura Torres; Martínez‐López, Joaquín; Barragán, Eva; Diaz, Rosa Ayala; Martínez‐Cuadrón, David; Montesinos, Pau

doi:10.1097/01.hs9.0000967440.83852.70

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Survival and follow-up data were analyzed as of May 31, 2022. De nition of 'Older' Patients 'Older' patients are variably de ned based on cut-offs ranging from 65 to 70 years in various guidelines and clinical trials. (10,11) Although the median age of onset of AML is approximately 68 years in published data, we selected a lower threshold of 55 years for this study. (2)This decision was based on previous data indicating a possibly lower median age of onset of AML in India.…”

Section: Methodsmentioning

confidence: 99%

Treatment challenges and outcomes of older patients with acute myeloid leukemia from India

Singh,

Lionel,

Jain

et al. 2024

Preprint

View full text Add to dashboard Cite

Globally, overall survival (OS) of older patients with AML continues to be suboptimal with very little data from India. In a multicenter registry analysis, we evaluated 712 patients with AML older than 55 years. Only 323 (45.3%) underwent further treatment, of which 239 (74%) received HMAs, and 60 (18%) received intensive chemotherapy (IC). CR was documented in 39% of those receiving IC and 42% after HMAs. Overall, 100 (31%) patients died within 60 days of diagnosis, most commonly due to progressive disease (47%) or infections (30%). After a median follow-up of 176 days, 228 (76%) of patients had discontinued treatment. At one year from diagnosis, 211 (65%) patients had died, and the median OS was 186 days (IQR, 137–234). Only 12 (3.7%) patients underwent stem cell transplantation. Survival was significantly lower for those older than 60 years (p < 0.001). Patients who died had a higher median age (p = .027) and baseline WBC counts (p = .006). Our data highlights suboptimal outcomes in older AML patients, which are evident from 55 years of age onwards, making it necessary to evaluate HMA and targeted agent combinations along with novel consolidation strategies to improve survival in this high-risk population.

show abstract

Section: Methodsmentioning

confidence: 99%

Treatment challenges and outcomes of older patients with acute myeloid leukemia from India

Singh,

Lionel,

Jain

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

S132: Updated Results of Ven-a-Qui Study: A Phase 1-2 Trial to Assess the Safety and Efficacy of Triplets for Newly Diagnosed Unfit Aml Patients: Azacitidine or Low-Dose Cytarabine With Venetoclax and Quizartinib

Abstract: Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.

Cited by 1 publication

References 0 publications

Treatment challenges and outcomes of older patients with acute myeloid leukemia from India

Treatment challenges and outcomes of older patients with acute myeloid leukemia from India

Contact Info

Product

Resources

About